Oppenheimer Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $60
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsInitiationPrice Target
Oppenheimer analyst Jay Olson initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Outperform rating and announces Price Target of $60.
Oppenheimer analyst Jay Olson initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Outperform rating and announces Price Target of $60.